Compile Data Set for Download or QSAR
maximum 50k data
Found 736 with Last Name = 'zumbrunn' and Initial = 'c'
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293232(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  3nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293234(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  4nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293222(2-(N-(2-cyano-4-methylphenyl)-3,4-dimethoxyphenyls...)
Affinity DataIC50:  4nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293230(2-(N-(6-chloro-3-methylbenzo[d]isothiazol-5-yl)-3,...)
Affinity DataIC50:  4.5nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50292965(2-(4-tert-butyl-N-p-tolylphenylsulfonamido)-N,N-di...)
Affinity DataIC50:  5nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293231(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  5nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293232(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  5nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293235(2-(N-(6-chloro-3-methylbenzo[d]isothiazol-5-yl)-3,...)
Affinity DataIC50:  5nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50292976(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  5nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293234(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  6nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293236(2-(N-(6-chloro-3-methylbenzo[d]isothiazol-5-yl)-3,...)
Affinity DataIC50:  7nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293233(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  7nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293236(2-(N-(6-chloro-3-methylbenzo[d]isothiazol-5-yl)-3,...)
Affinity DataIC50:  8nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293235(2-(N-(6-chloro-3-methylbenzo[d]isothiazol-5-yl)-3,...)
Affinity DataIC50:  8nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293224(2-(N-(2-chloro-5-methylphenyl)-3,4-dimethoxyphenyl...)
Affinity DataIC50:  8nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620313(US20230295182, Example 1.45 | US20230295182, Examp...)
Affinity DataIC50:  10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293216(2-(N-(2-cyano-5-(dimethylamino)phenyl)-3,4-dimetho...)
Affinity DataIC50:  10nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293233(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  12nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620309(US20230295182, Example 1.41 | US20230295182, Examp...)
Affinity DataIC50:  12nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632517((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50:  12.5nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632544((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2...)
Affinity DataIC50:  12.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632510((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50:  13.6nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632552((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl...)
Affinity DataIC50:  14.3nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632505((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(2...)
Affinity DataIC50:  14.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620311(US20230295182, Example 1.43 | US20230295182, Examp...)
Affinity DataIC50:  15nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632502((2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(2,3-...)
Affinity DataIC50:  15.1nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632547((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl...)
Affinity DataIC50:  16.4nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632478((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3...)
Affinity DataIC50:  16.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620359(US20230295182, Example 2.09 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  17nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50293231(2-(N-(2-chloro-5-(dimethylamino)phenyl)-3,4-dimeth...)
Affinity DataIC50:  17nMAssay Description:Inhibition of human OX1 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632513((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3...)
Affinity DataIC50:  17.1nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632606((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(2...)
Affinity DataIC50:  17.1nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632476((2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(...)
Affinity DataIC50:  17.3nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632519((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(4...)
Affinity DataIC50:  17.4nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620361(US20230295182, Example 2.11 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  19nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Actelion Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50292977(2-(3,4-dimethoxy-N-p-tolylphenylsulfonamido)-N,N-d...)
Affinity DataIC50:  19nMAssay Description:Inhibition of human OX2 receptor expressed in CHO cells assessed as intercellular calcium mobilization by FLIPR assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632551((2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(...)
Affinity DataIC50:  19.3nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632546((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl...)
Affinity DataIC50:  19.8nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632553((2R,3R,4S,5R,6R)-4-(4-(4-chloro-3,5-difluorophenyl...)
Affinity DataIC50:  19.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620360(US20230295182, Example 2.10 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632487((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3...)
Affinity DataIC50:  21.2nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632511((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50:  21.2nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632508((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50:  21.7nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632503((2R,3R,4S,5R,6R)-N-(3-chloro-5-cyanophenyl)-4-(4-(...)
Affinity DataIC50:  21.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632550((2R,3R,4S,5R,6R)-N-(3,5-dichlorophenyl)-4-(4-(3,5-...)
Affinity DataIC50:  22.7nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632491((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-4-(4-(3...)
Affinity DataIC50:  22.9nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632542((2R,3R,4S,5R,6R)-2-((3,5-dichlorophenyl)((1S,2S)-2...)
Affinity DataIC50:  23nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632457((2R,3R,4S,5R,6R)-N-(3-bromo-5-cyanophenyl)-5-hydro...)
Affinity DataIC50:  23nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632507((2R,3R,4S,5R,6R)-4-(4-(4-bromo-2,3-difluorophenyl)...)
Affinity DataIC50:  23.7nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM632543((2R,3R,4S,5R,6R)-2-((3-chloro-5-cyanophenyl)((1S,2...)
Affinity DataIC50:  25.3nMAssay Description:The inhibitory activity of compounds is determined in competitive binding assays. This spectrophotometric assay measures the binding of biotinylated ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 736 total ) | Next | Last >>
Jump to: